Compare Mesoblast Limited (MESO) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Wipro Limited — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Wipro Limited trades at $1.86 (market cap $18.49B). The key difference: Wipro Limited is far larger — about 8.5× Mesoblast Limited's market cap, and Wipro Limited pays a 4.68% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | WIT | |
|---|---|---|
Market Cap | $2.17B | $18.49B |
Sector | Technology | Technology |
52-Week High | $20.96 | $3.06 |
52-Week Low | $12.88 | $1.82 |
Enterprise Value | $2.17B | $16.42B |
Dividend Yield | — | 4.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
WIT trades at $1.855, down 0.27% with bearish technical signals. Recent quarters show earnings misses against expectations, though 2025 revenue was $890.88B with net income of $131.35B. Valuation ratios appear reasonable with P/E of 13.97 and P/B of 1.96. Analyst consensus is mixed with 19% buy ratings amid concerns about client spending and AI investments.
The outlook remains cautious due to earnings volatility and competitive pressures. Investment appeal hinges on AI partnership execution and margin stabilization, while risks include geopolitical uncertainty and tech spending constraints. Cash flow strength provides some buffer against near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
